Peptron 2026 1Q: Sales Growth on Lupone Launch, Operating Loss Widens but Cash Position Strong
2026 Q1 revenue KRW 19.7B (vs KRW 16.2B in Q1 2025, +21.4%). Launch of Lupone (prostate cancer) drove pharmaceutical segment to 59.3% of total revenue.
Operating loss KRW 5.8B (vs KRW 4.4B loss in Q1 2025). Net loss KRW 6.1B (vs KRW 3.3B). R&D expense KRW 4.4B (227% of revenue).
Total assets KRW 174.5B, liabilities KRW 38.5B, equity KRW 136B. Cash and cash equivalents KRW 10.6B; total liquid financial assets KRW 47.6B. Net cash position (borrowings minus cash) of KRW 1.5B.
Terminated license agreement with Yuhan for diabetes drug PT302 (March 13, 2026); regained exclusive rights and clinical data, enabling potential global out-licensing.
Exchangeable bonds outstanding KRW 24.2B (conversion price KRW 326,895, maturity 2030). Held 73,961 treasury shares for exchange. Granted 60,000 new stock options (exercise price KRW 316,500).
Pipeline: PT320 (Parkinson's) Ph2 completed in Korea; PT403 (diabetes/obesity) in preclinical; PND3174 (achondroplasia) in preclinical; acromegaly drug candidate in formulation development.
No separate disclosure on BIS ratio or NPL. Credit rating BB- (Korea Data).